Kuur TherapeuticsProduct Overview

Our Pipeline

Therapy Type
Product
Target Tumors
Target Antigens
Preclinical
Phase 1
Phase 2 & 3
Upcoming Milestones
Autologous
KUR-501
Neuroblastoma
GD2
Complete 4th dose level; 1H 2021
Allogeneic
KUR-502
Hematological malignancies
CD19
Complete 1st dose level: 1H 2021
Allogeneic
KUR-503
Liver cancer
GPC3
File IND; 2H 2021
KUR-501: Autologous

We are developing a GD2-CAR NKT autologous product (KUR-501) for the treatment of neuroblastoma. A first-in-human study is underway at Baylor College of Medicine (BCM) at Texas Children’s Hospital in Houston, TX.

CAR-NKT in Relapsed or Refractory High Risk GD2+ Neuroblastoma
KUR-501 CAR-NKT Therapy
  • Autologous CAR-NKT cells targeting GD2
  • Cells engineered to express IL-15 to improve persistence and efficacy
GD2 Biology and Tumor Expression
  • Clinically validated target widely expressed on neuroblastoma cells
  • Limited expression on normal tissue
Unmet Medical Need
  • Neuroblastoma causes almost 15% of childhood cancer related deaths
  • Over half of all children with neuroblastoma have high risk disease
  • No standard therapy for patients with R/R high risk neuroblastoma
  • R/R high risk disease patients have a poor prognosis
    • Median survival of 1-3 years
Clinical Development Plan
  • Preclinical evaluation in SCLC, malignant melanoma & other indications
KUR-502: Allogeneic

We are developing an off-the-shelf CD19 targeted allogeneic CAR-NKT product for the treatment of relapsed, refractory CD19-positive malignancy.

Off-the-Shelf CAR-NKT in Relapsed or Refractory CD19+ Malignancies
KUR-502 CAR-NKT Therapy
  • Allogenic CAR-NKT cells targeting CD19
  • Cell engineering to:
    • Express IL-15 to improve persistence and efficacy
    • Down-regulate MHC modules and diminish allo-reacitvity
CD19 Biology and Tumor Expression
  • Clinically validated target expressed on B cells and related malignancies
  • On target tissue tumor toxicity limited to B cell aplasia
Unmet Medical Need
  • Autologous CAR-T products have complicated logistics which can lead to treatment delays
  • Bridging chemotherapy required during product manufacturing
  • Autologous CAR-T product quality can be highly variable
Clinical Development Plan
  • Evaluating safety, cell expansion and initial signs of therapeutic activity
KUR-503: Allogeneic

We are developing an off-the-shelf GPC3 targeted allogeneic CAR-NKT product for the treatment of advanced hepatocellular (liver) cancer.

Off-the-Shelf CAR-NKT Cell Therapy of Hepatocellular Carcinoma (HCC)
KUR-503 CAR-NKT Therapy
  • Allogeneic CAR-NKT cells targeting GPC3
  • Cells engineered to:
    • Express IL-15 to improve persistence and efficacy
GPC3 Biology and Tumor Expression
  • Transmembrane heparan sulfate proteoglycan (Glypican-3)
  • Expressed on the majority (>70%) of HCC tumors
  • May play a role in HCC tumor progression
  • Antibodies against GPC3 active in phase 1
  • No expression on normal hepatic tissue
  • Expressed on very limited adult tissue at low levels
  • Expressed on placenta and some fetal tissue
Unmet Medical Need
  • Multiple agents approved for 1st or 2nd line advanced HCC but response rates are generally <20% and overall survival generally < 1 year
GPC3 Expression in HCC (Diffuse and Membranous Patterns)

GPC3 expression in HCC (diffuse and membranous patterns)

CAR-NKT APPROACH

We are developing a wide range of CAR-NKT cell products to treat different types of highly prevalent tumors. The CAR-NKT cell product candidates include both autologous (KUR-501) and allogeneic (KUR-502 and KUR-503) products.
More Info

Kuur Therapeutics Partnering

Kuur Therapeutics is actively seeking licensing and partnering opportunities, drawing on global immunotherapy expertise, to explore and advance the therapeutic possibilities for our NKT cell immunotherapy products.
More Info